Heltzen on Grow Everything podcast, episode #201
heltzennutraceuticalspress clippingsvideoNCT
Grow Everything podcast: Out of Cell Experience - Heltzen Drives Pure ChemistryOctober 2, 2026
WTR: INITIATION OF COVERAGE REPORT
investorpress clippings
WTR: Converting Cell-Free Science into a Scalable and Repeatable Commercial OpportunityOctober 1, 2026
Globe and Mail: eXoZymes Sets Date for 2026 Shareholders Meeting
investorpress clippings
The Globe and Mail: eXoZymes Sets Date for 2026 Shareholders MeetingSeptember 19, 2026
Pharma Manufacturing: EXOZ selects Curia
press clippingsNCT
Pharma Manufacturing: eXoZymes picks Curia as commercial-scale manufacturing partnerSeptember 14, 2026
BioTuesdays: eXoZymes selects Curia as CDMO for NCT
press clippingsNCT
BioTuesdays: EXOZ selects Curia as CDMO for NCTSeptember 11, 2026
PharmaSource podcast featuring EXOZ CCO, Perriman
investorpodcastperrimanNCT
PharmaSource podcast: How EXOZ Is Running a 10-CDMO RFP for CDMO SelectionSeptember 9, 2026
Dr. Paul Opgenorth from eXoZymes at Curia in Italy
investorperrimanNCT
eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCTSeptember 8, 2026
WBMI: Scaling without Cells
investornutraceuticalspress clippingsperrimanNCT
World Bio Market Insights: Scaling without CellsSeptember 3, 2026
Inside eXoZymes’ Strategic Shift: Building a Compounding Value Flywheel
investorpress clippingsNCT
Slack Capital: Inside EXOZ’ strategic shift - building a compounding value flywheelAugust 27, 2026
WTR: EXOZ 2Q26 update - from platform validation to commercial execution
investorpress clippingsNCT
WTR: EXOZ 2Q26 update - from platform validation to commercial executionAugust 25, 2026
Previous page
Page 1 of 16
Next page